OBJECTIVE: In a previous analysis involving protocol ANRS 12154, interindividual variability in steady-state nevirapine clearance among HIV-infected Cambodians was partially explained by CYP2B6 516G→T (CYP2B6*6). Here, we examine whether additional genetic variants predict nevirapine clearance in this cohort. METHODS: Analyses included Phnom Penh ESTHER (Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau) cohort participants who had consented for genetic testing. All participants were receiving nevirapine plus two nucleoside analogs. The mean individual nevirapine clearance estimates were derived from a population model developed on nevirapine concentrations at 18 and 36 months of therapy. Polymorphisms were assayed in ABCB1, CYP2A6, CYP2B6, CYP2C19, CYP3A4, CYP3A5, and NR1I2. RESULTS: Of 198 assayed loci, 130 were polymorphic. Among 129 individuals with evaluable genetic data, nevirapine clearance ranged from 1.06 to 5.00 l/h in 128 individuals and was 7.81 l/h in one individual. In bivariate linear regression, CYP2B6 516G→T (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5×10). In a multivariate linear regression model conditioned on CYP2B6 516G→T, independent associations were identified with CYP2B6 rs7251950, CYP2B6 rs2279343, and CYP3A4 rs2687116. The CYP3A4 association disappeared after censoring the outlier clearance value. A model that included CYP2B6 516G→T (P=1.0×10), rs7251950 (P=4.8×10), and rs2279343 (P=7.1×10) explained 11% of interindividual variability in nevirapine clearance. CONCLUSION: Among HIV-infected Cambodians, several CYP2B6 polymorphisms were associated independently with steady-state nevirapine clearance. The prediction of nevirapine clearance was improved by considering several polymorphisms in combination.
OBJECTIVE: In a previous analysis involving protocol ANRS 12154, interindividual variability in steady-state nevirapine clearance among HIV-infected Cambodians was partially explained by CYP2B6 516G→T (CYP2B6*6). Here, we examine whether additional genetic variants predict nevirapine clearance in this cohort. METHODS: Analyses included Phnom Penh ESTHER (Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau) cohort participants who had consented for genetic testing. All participants were receiving nevirapine plus two nucleoside analogs. The mean individual nevirapine clearance estimates were derived from a population model developed on nevirapine concentrations at 18 and 36 months of therapy. Polymorphisms were assayed in ABCB1, CYP2A6, CYP2B6, CYP2C19, CYP3A4, CYP3A5, and NR1I2. RESULTS: Of 198 assayed loci, 130 were polymorphic. Among 129 individuals with evaluable genetic data, nevirapine clearance ranged from 1.06 to 5.00 l/h in 128 individuals and was 7.81 l/h in one individual. In bivariate linear regression, CYP2B6 516G→T (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5×10). In a multivariate linear regression model conditioned on CYP2B6 516G→T, independent associations were identified with CYP2B6rs7251950, CYP2B6rs2279343, and CYP3A4rs2687116. The CYP3A4 association disappeared after censoring the outlier clearance value. A model that included CYP2B6 516G→T (P=1.0×10), rs7251950 (P=4.8×10), and rs2279343 (P=7.1×10) explained 11% of interindividual variability in nevirapine clearance. CONCLUSION: Among HIV-infected Cambodians, several CYP2B6 polymorphisms were associated independently with steady-state nevirapine clearance. The prediction of nevirapine clearance was improved by considering several polymorphisms in combination.
Authors: David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta Journal: AIDS Date: 2004-12-03 Impact factor: 4.177
Authors: Sandra G Heil; Marchina E van der Ende; Paul W Schenk; Ilse van der Heiden; Jan Lindemans; David Burger; Ron H N van Schaik Journal: Ther Drug Monit Date: 2012-04 Impact factor: 3.681
Authors: Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Julia Kirchheiner; Christian Klein; Ingolf Meineke; Johanna Sasse; Ulrich M Zanger; Thomas E Mürdter; Ivar Roots; Jürgen Brockmöller Journal: Pharmacogenetics Date: 2003-10
Authors: Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: Phumla Z Sinxadi; Paul D Leger; Helen M McIlleron; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens; David W Haas Journal: Br J Clin Pharmacol Date: 2015-05-28 Impact factor: 4.335
Authors: Saran Vardhanabhuti; Edward P Acosta; Heather J Ribaudo; Patrice Severe; Umesh Lalloo; Nagalingeshwaran Kumarasamy; Frank Taulo; Joseph Kabanda; Olola Oneko; Prudence Ive; Pradeep Sambarey; Ellen S Chan; Jane Hitti; Francis Hong; Deborah McMahon; David W Haas Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226
Authors: Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: David W Haas; Patrice Severe; Marc Antoine Jean Juste; Jean William Pape; Daniel W Fitzgerald Journal: J Antimicrob Chemother Date: 2014-04-02 Impact factor: 5.790